Investigating the Seroprevalence of HBV and HCV infection in Potential Donors: An6r tn e5r Study from Iranian Tissue Bank and Research Center (2014-2021)
-
Omid Salahi Ardekani
,
Alireza Etrati Kooshali
,
Saba Seyedi
,
Ali Vasheghani Farahani
,
Nazanin Mohammadlo
,
Negar Asghari Hosori
,
Sheida Sarrafzadeh
,
Sedigheh Poursaleh
,
Maryam Karami
,
Mahsa Salasi
,
Ahmadreza Sadeghi Sadeghi
Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major contributors to liver disease and hepatocellular carcinoma (HCC), affecting millions worldwide. Transmission routes and clinical outcomes vary between the two viruses, with both posing significant challenges in transplantation. Understanding the seroprevalence of HBV and HCV is crucial for effective pre-transplant screening and post-transplant management to prevent disease transmission and recurrence. The present study aimed to investigate the prevalence of HBV and HCV in potential donors referred to the Iranian Tissue Bank and Research Center (ITBRC).
Methods: The study population was potential donors referred to ITBRC between 2014 and 2021, including two groups: brain death donors and forensic donors referred from the Iranian Legal Medicine Organization. For HBV, HBsAg and HBsAb; and for HCV, HCV-Ab were detected by ELISA.
Results: A total of 3862 individuals were studied (32.4% female and 67.6% male), including 1349 (34.9%) brain death and 2513 (65.1%) circulatory death donors. Analysis showed 1.19 times higher rates of HCV infection in women than in men, but this was not statistically significant. Logistic regression showed no significant effects of donor type on HCV infection rates. For HBV, brain death subjects had over three times higher odds of HBsAg-positive tests compared to circulatory death (OR = 3.06, p-value < 0.05). Additionally, female cases had lower odds of an HBsAg-positive test compared to males (OR = 0.56). The odds of a positive HBsAg test in brain death cases were 2.7 times higher than in circulatory death, with 3.49% of cases being positive for HBsAg and HBsAb test results.
Conclusion: In conclusion, this retrospective study demonstrated a higher prevalence of HBV-positive tests in brain death donors compared to circulatory death donors, with female donors showing lower odds of HBsAg-positive tests compared to males.
[1] Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 1985;317(6037):489-95. https://doi.org/10.1038/317489a0
[2] Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(S5):S13-21. https://doi.org/10.1002/hep.22881
[3] Ayele B, Weldehanna D, Demsiss W. Serological Evidence and Associated Factors of Hepatitis B Virus and Hepatitis C Virus Among Waste Handlers: A Cross-Sectional Study from Northeastern Ethiopia. Infect Drug Resist. 2023;16:4881-90. https://doi.org/10.2147/IDR.S416409
[4] Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(S1):S21-9. https://doi.org/10.1002/hep.1840360704
[5] Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436(7053):973-8. https://doi.org/10.1038/nature04083
[6] Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(S3):62S-5S. https://doi.org/10.1002/hep.510260711
[7] Lanini S, Easterbrook PJ, Zuin M, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22(10):833-8. https://doi.org/10.1016/j.cmi.2016.07.035
[8] Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215-29. https://doi.org/10.1038/nri1573
[9] Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg. 2002;66(4):389-93. https://doi.org/10.4269/ajtmh.2002.66.389
[10] Lok ASF, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology. 2004;39(3):857-61. https://doi.org/10.1002/hep.20110
[11] Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon. 2012;12(10 HCC):e7635. https://doi.org/10.5812/hepatmon.7635
[12] Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12(8):1192-204. https://doi.org/10.1002/lt.20865
[13] Bain V. Hepatitis B in transplantation. Transpl Infect Dis. 2000;2(4):153-65. https://doi.org/10.1034/j.1399-3062.2000.020402.x
[14] Ayoub WS, Martin P, Bhamidimarri KR. Hepatitis B Virus Infection and Organ Transplantation. Gastroenterol Hepatol (N Y). 2018;14(1):33-40.
[15] Amini Kafi-Abad S, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion. 2009;49(10):2214-20. https://doi.org/10.1111/j.1537-2995.2009.02245.x
[16] Aghamohamadi A, Montazeri M, Akbari M. Prevalence of hepatitis B and hepatitis C in blood donors at Semnan province from 2008 to 2011. Koomesh. 2014;15(2):162-7.
[17] Etminan A, Naghibzadeh-Tahami A, Seyed Askari SM. The association between the prevalence of transfusion transmitted infections and characteristics of infected blood donors in Kerman, Iran. J Kerman Univ Med Sci. 2019;26(5):377-83.
[18] Mohammadi Tahroodi F, Zolfaghari MR, Matini E, Sabbagh A, Akbarpour M. The prevalence of hepatitis B, hepatitis C and AIDS in blood donors in Ilam province: a retrospective study. Iran J Virol. 2018;12(1):32-9.
[19] Azadbakht M, Moosazadeh M, Shojaee J, Aliramzany M, Naghshvarian M, Sadeghi F, et al. Seroprevalence and trend of HBV, HCV, and HIV infections among blood donors of Fars province, Iran (2006-2018). Ethiop J Health Sci. 2020;30(3):401-8. https://doi.org/10.4314/ejhs.v30i3.11
[20] Yin S, Chen X, Yang Y, Xu X, Wei W. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis. PLoS Med. 2023;20(3):e1004196. https://doi.org/10.1371/journal.pmed.1004196
[21] Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716-26. https://doi.org/10.1002/lt.23411
[22] Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation. Gastroenterology. 2007;132(3):931-7. https://doi.org/10.1053/j.gastro.2007.01.005
[23] Shah G, Demetris AJ, Irish W, Scheffel J, Mimms L, Van Thiel DH. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology. 1992;103(1):323-9. https://doi.org/10.1016/0016-5085(92)91130-V
[24] Tigabu A, Engda T, Mekonnen F. Seroprevalence of transfusion transmissible viral infections (HIV, HBV and HCV) among voluntary blood donors at University of Gondar Comprehensive Specialized Hospital, Gondar; Northwest Ethiopia. BMC Infect Dis. 2019;19(1):393. https://doi.org/10.1186/s12879-019-3950-2
[25] Almawi WY, Qadi AA, Tamim H, Ameen G, Bu-Ali A, Arrayid S, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among dialysis patients in Bahrain and Saudi Arabia. Transplant Proc. 2004;36(6):1824-6. https://doi.org/10.1016/j.transproceed.2004.07.019
[26] Arora D, Arora B, Khetarpal A. Seroprevalence of HIV, HBV, HCV and syphilis in blood donors in Southern Haryana. Indian J Pathol Microbiol. 2010;53(2):308-9. https://doi.org/10.4103/0377-4929.64295
[27] Kliem V, Burg M, Haller H, Suwelack B, Abendroth D, Fritsche L, et al. Relationship of Hepatitis B or C Virus Prevalences, Risk Factors, and Outcomes in Renal Transplant Recipients: Analysis of German Data. Transplant Proc. 2008;40(4):909-14. https://doi.org/10.1016/j.transproceed.2008.03.031
[28] Tiwari BR, Ghimire P, Karki S, Shrestha R, Poudel A, Rajkarnikar M. Seroprevalence of HBV and HCV in blood donors: A study from regional blood transfusion services of Nepal. Asian J Transfus Sci. 2010;4(2):91-3. https://doi.org/10.4103/0973-6247.67026
[29] Calderón GM, González-Velázquez F, González-Bonilla CR, Novoa-López G, Terán-Puig H, Rojas-Montes O, et al. Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico. Transfusion. 2009;49(10):2200-7. https://doi.org/10.1111/j.1537-2995.2009.02248.x
[30] Bae E, Jeong D, Kim J, Lee H, Park K, Yang J, et al. Prevalence and clinical significance of occult hepatitis B virus infection among renal transplant recipients in Korea. Scand J Infect Dis. 2012;44(10):788-92. https://doi.org/10.3109/00365548.2012.680488
[31] Abate M, Wolde T. Seroprevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis among blood donors at Jigjiga Blood Bank, eastern Ethiopia. Ethiop J Health Sci. 2016;26(2):155-62. https://doi.org/10.4314/ejhs.v26i2.9
[32] Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Agüero F, et al. Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study. Am J Transplant. 2012;12(7):1866-76. https://doi.org/10.1111/j.1600-6143.2012.04028.x
[2] Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(S5):S13-21. https://doi.org/10.1002/hep.22881
[3] Ayele B, Weldehanna D, Demsiss W. Serological Evidence and Associated Factors of Hepatitis B Virus and Hepatitis C Virus Among Waste Handlers: A Cross-Sectional Study from Northeastern Ethiopia. Infect Drug Resist. 2023;16:4881-90. https://doi.org/10.2147/IDR.S416409
[4] Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(S1):S21-9. https://doi.org/10.1002/hep.1840360704
[5] Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436(7053):973-8. https://doi.org/10.1038/nature04083
[6] Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(S3):62S-5S. https://doi.org/10.1002/hep.510260711
[7] Lanini S, Easterbrook PJ, Zuin M, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22(10):833-8. https://doi.org/10.1016/j.cmi.2016.07.035
[8] Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215-29. https://doi.org/10.1038/nri1573
[9] Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg. 2002;66(4):389-93. https://doi.org/10.4269/ajtmh.2002.66.389
[10] Lok ASF, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology. 2004;39(3):857-61. https://doi.org/10.1002/hep.20110
[11] Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon. 2012;12(10 HCC):e7635. https://doi.org/10.5812/hepatmon.7635
[12] Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12(8):1192-204. https://doi.org/10.1002/lt.20865
[13] Bain V. Hepatitis B in transplantation. Transpl Infect Dis. 2000;2(4):153-65. https://doi.org/10.1034/j.1399-3062.2000.020402.x
[14] Ayoub WS, Martin P, Bhamidimarri KR. Hepatitis B Virus Infection and Organ Transplantation. Gastroenterol Hepatol (N Y). 2018;14(1):33-40.
[15] Amini Kafi-Abad S, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion. 2009;49(10):2214-20. https://doi.org/10.1111/j.1537-2995.2009.02245.x
[16] Aghamohamadi A, Montazeri M, Akbari M. Prevalence of hepatitis B and hepatitis C in blood donors at Semnan province from 2008 to 2011. Koomesh. 2014;15(2):162-7.
[17] Etminan A, Naghibzadeh-Tahami A, Seyed Askari SM. The association between the prevalence of transfusion transmitted infections and characteristics of infected blood donors in Kerman, Iran. J Kerman Univ Med Sci. 2019;26(5):377-83.
[18] Mohammadi Tahroodi F, Zolfaghari MR, Matini E, Sabbagh A, Akbarpour M. The prevalence of hepatitis B, hepatitis C and AIDS in blood donors in Ilam province: a retrospective study. Iran J Virol. 2018;12(1):32-9.
[19] Azadbakht M, Moosazadeh M, Shojaee J, Aliramzany M, Naghshvarian M, Sadeghi F, et al. Seroprevalence and trend of HBV, HCV, and HIV infections among blood donors of Fars province, Iran (2006-2018). Ethiop J Health Sci. 2020;30(3):401-8. https://doi.org/10.4314/ejhs.v30i3.11
[20] Yin S, Chen X, Yang Y, Xu X, Wei W. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis. PLoS Med. 2023;20(3):e1004196. https://doi.org/10.1371/journal.pmed.1004196
[21] Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716-26. https://doi.org/10.1002/lt.23411
[22] Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation. Gastroenterology. 2007;132(3):931-7. https://doi.org/10.1053/j.gastro.2007.01.005
[23] Shah G, Demetris AJ, Irish W, Scheffel J, Mimms L, Van Thiel DH. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology. 1992;103(1):323-9. https://doi.org/10.1016/0016-5085(92)91130-V
[24] Tigabu A, Engda T, Mekonnen F. Seroprevalence of transfusion transmissible viral infections (HIV, HBV and HCV) among voluntary blood donors at University of Gondar Comprehensive Specialized Hospital, Gondar; Northwest Ethiopia. BMC Infect Dis. 2019;19(1):393. https://doi.org/10.1186/s12879-019-3950-2
[25] Almawi WY, Qadi AA, Tamim H, Ameen G, Bu-Ali A, Arrayid S, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among dialysis patients in Bahrain and Saudi Arabia. Transplant Proc. 2004;36(6):1824-6. https://doi.org/10.1016/j.transproceed.2004.07.019
[26] Arora D, Arora B, Khetarpal A. Seroprevalence of HIV, HBV, HCV and syphilis in blood donors in Southern Haryana. Indian J Pathol Microbiol. 2010;53(2):308-9. https://doi.org/10.4103/0377-4929.64295
[27] Kliem V, Burg M, Haller H, Suwelack B, Abendroth D, Fritsche L, et al. Relationship of Hepatitis B or C Virus Prevalences, Risk Factors, and Outcomes in Renal Transplant Recipients: Analysis of German Data. Transplant Proc. 2008;40(4):909-14. https://doi.org/10.1016/j.transproceed.2008.03.031
[28] Tiwari BR, Ghimire P, Karki S, Shrestha R, Poudel A, Rajkarnikar M. Seroprevalence of HBV and HCV in blood donors: A study from regional blood transfusion services of Nepal. Asian J Transfus Sci. 2010;4(2):91-3. https://doi.org/10.4103/0973-6247.67026
[29] Calderón GM, González-Velázquez F, González-Bonilla CR, Novoa-López G, Terán-Puig H, Rojas-Montes O, et al. Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico. Transfusion. 2009;49(10):2200-7. https://doi.org/10.1111/j.1537-2995.2009.02248.x
[30] Bae E, Jeong D, Kim J, Lee H, Park K, Yang J, et al. Prevalence and clinical significance of occult hepatitis B virus infection among renal transplant recipients in Korea. Scand J Infect Dis. 2012;44(10):788-92. https://doi.org/10.3109/00365548.2012.680488
[31] Abate M, Wolde T. Seroprevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis among blood donors at Jigjiga Blood Bank, eastern Ethiopia. Ethiop J Health Sci. 2016;26(2):155-62. https://doi.org/10.4314/ejhs.v26i2.9
[32] Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Agüero F, et al. Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study. Am J Transplant. 2012;12(7):1866-76. https://doi.org/10.1111/j.1600-6143.2012.04028.x
| Files | ||
| Issue | Vol 1 No 1 (2026) | |
| Section | Review Article(s) | |
| Keywords | ||
| HBV HCV Prevalence Transplantation Brain death | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Salahi Ardekani O, Etrati Kooshali A, Seyedi S, Vasheghani Farahani A, Mohammadlo N, Asghari Hosori N, Sarrafzadeh S, Poursaleh S, Karami M, Salasi M, Sadeghi AS. Investigating the Seroprevalence of HBV and HCV infection in Potential Donors: An6r tn e5r Study from Iranian Tissue Bank and Research Center (2014-2021). ipj. 2026;1(1):39-44.
